Inverness Medical Innovations Acquires Alere Medical

WALTHAM, Mass., Nov. 19 Inverness MedicalInnovations, Inc. (Amex: IMA) today announced the completion of itsacquisition of Alere Medical, Inc. at a purchase price of $302 million,comprising approximately $128 million in cash and $174 million in Invernesscommon stock and assumed options. Alere, headquartered in Reno, Nevada,provides health and care management services and programs to healthcareorganizations in helping patients with chronic illnesses manage theirconditions.

About Inverness

By developing new capabilities in near-patient diagnosis, monitoring andhealth management, Inverness Medical Innovations enables individuals to takecharge of improving their health and quality of life. A global leader inrapid point-of-care diagnostics, Inverness' products, as well as its newproduct development efforts, focus on infectious disease, cardiology,oncology, drugs of abuse and women's health. Inverness is headquartered inWaltham, Massachusetts. For additional information on Inverness MedicalInnovations, please visit www.invernessmedical.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaningof the federal securities laws, including statements regarding potentialsynergies and benefits of the proposed business combination and potentialmarket growth. These statements reflect Inverness' current views with respectto future events and are based on Inverness' management's current assumptionsand information currently available. Actual results may differ materially dueto numerous factors including, without limitation, risks associated withmarket and economic conditions; competition; Inverness' ability to integratethis and other acquisitions and to realize expected benefits; Inverness'ability to continue to successfully develop and manufacture diagnostic testingproducts and to commercialize products; and the risks and uncertaintiesdescribed in Inverness' annual report on Form 10-K, as amended, for the yearended December 31, 2006, and other factors identified from time to time in itsperiodic filings with the Securities and Exchange Commission. Invernessundertakes no obligation to update any forward-looking statements containedherein.

SOURCE Inverness Medical Innovations

Latest Press Release on General News

Boehringer Ingelheim and Palatin Technologies to Develop Potential First-in-class Melanocortin Receptor Targeted Treatment for Patients With Retinal Diseases

· Collaboration strengthens Boehringer’s pipeline in Eye Health. · Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatig...

Echosens and Novo Nordisk Advance Partnership to Increase Awareness and Early Diagnosis of MASH

PR Newswire WESTBOROUGH, Mass., Aug. 18, 2025 WESTBOROUGH, Mass., Aug. 18, 2025 /PRNewswire/ -- Echosens, the leader in non-invasive liver diagnostics, and Novo Nordisk are strengthe...

Minimally Invasive Procedure Relieves Painful Symptoms of Knee Osteoarthritis

PR Newswire NEW YORK, Aug. 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- A procedure performed under mild sedation in less than two hours by an interventional radiologist relieves...

IBS in America: Despite advances, IBS remains a burden for many millions

PR Newswire BETHESDA, Md., Aug. 12, 2025 A new AGA-sponsored survey conducted by The Harris Poll, a Stagwell (STGW) agency, reveals that IBS symptoms disrupt patients' productivity...

Breakthroughs on the Horizon: Global Experts to Tackle Fastest-Growing Brain Disease at Major International Congress in Honolulu

PR Newswire HONOLULU, Aug. 5, 2025 The world's leading authorities on Parkinson's disease and other movement disorders — some of the most challenging and fastest-growing neurological...